Comparative Efficacy and Bioequivalence of Novel H1-Antihistamine Bepotastine Salts (Nicotinate and Salicylate)

REFERENCES

• Amidon, G. L., Lennernas, H., Shah, V. P., and Crison, J. R. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12: 413–420.
   PubMed Web of Science ®Google Scholar
• Amighi, K., Timmermans, J., Puigdevall, J., Baltes, E., and Moes, A. J. 1998. Peroral sustained-release film-coated pellets as a means to overcome physicochemical and biological drug-related problems. I. In vitro development and evaluation. Drug Dev. Ind. Pharm. 24: 509–515.
   PubMed Web of Science ®Google Scholar
• Anderson, B. D., and Flora, K. P. 1996. Preparation of water-soluble compounds through salt formation. In The practice of medicinal chemistry, ed. C. G. Wermuth, 739–754. London, UK: Academic Press.
   Google Scholar
• Andoh, T., and Kuraishi, Y. 2006. Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice. Eur. J. Pharmacol. 54: 59–64.
   Web of Science ®Google Scholar
• Anthes, J. C., Gilchrest, H., Richard, C., Eckel, S., Hesk, D., West, R.E. Jr, Williams, S. M., Greenfeder, S., Billah, M., Kreutner, W., and Egan, R. E. 2002. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur. J. Pharmacol. 449: 229–237.
   PubMed Web of Science ®Google Scholar
• Avdeef, A. 2003. Absorption and drug development, 116–246. New York, NY: Wiley-Interscience.
   Google Scholar
• Balbach, S., and Korn, C. 2004. Pharmaceutical evaluation of early development candidates “the 100 mg-approach.” Int. J. Pharm. 275: 1–12.
   PubMed Web of Science ®Google Scholar
• Bastin, R. J., Bowker, M. J., and Slater, B. J. 2000. Salt selection and optimisation procedures for pharmaceutical new chemical entities. Org. Proc. Res. Dev. 4: 427–435.
   Web of Science ®Google Scholar
• Berge, S. M., Bighley, L. D., and Monkhouse, D. C. 1977. Pharmaceutical salts. J. Pharm. Sci. 66: 1–19.
   PubMed Web of Science ®Google Scholar
• Bighley, L. D., Berge, S. M., and Monkhouse, D. C. 1996. Salt forms of drugs and absorption. In Encyclopaedia of pharmaceutical technology, ed. J. Swarbrick and J. Boylan, vol. 13, 453–499. New York, NY: Marcel Dekker.
   Google Scholar
• Bowker, M. J. 2002. A procedure for salt selection and optimization. In Handbook of pharmaceutical salts: Properties, selection and use, ed. P.H. Stahl and C. G. Wermuth, 161–189. Weinheim, Germany: Wiley-VCH.
   Google Scholar
• Byrn, S., Pfeiffer, L. R., Ganey, L. M., Hoiberg, C., and Poochikian, G. 1995. Pharmaceutical solids: A strategic approach to regulatory considerations. Pharm. Res. 12: 945–954.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. 2009. Pharmacology/toxicology review and evaluation. Comments on N22288 bepotastine besilate bepreve. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022288s000_pharmr.pdf
   Google Scholar
• Chen, C. Y., Reamer, R. A., Chilenski, J. R., and McWilliams, J. C. 2003. Highly enantioselective hydrogenation of aromatic-heteroaromatic ketones. Org. Lett. 5: 5039–5042.
   PubMed Web of Science ®Google Scholar
• David, S. E., Timmins, P., and Conway, B. R. 2012. Impact of the counterion on the solubility and physicochemical properties of salts of carboxylic acid drugs. Drug Dev. Ind. Pharm. 38: 93–103.
   PubMed Web of Science ®Google Scholar
• Di, L., Kerns, E. H., and Carter, G. T. 2009. Drug-like property concepts in pharmaceutical design. Curr. Pharm. Des. 15: 2184–2194.
   PubMed Web of Science ®Google Scholar
• Fahr, A., and Liu, X. 2007. Drug delivery strategies for poorly water-soluble drugs. Expert Opin. Drug Deliv. 4: 403–416.
   PubMed Web of Science ®Google Scholar
• Froimowitz, M., Gu, Y., Dakin, L. A., Kelley, C. J., Parrish, D., and Deschamps, J. R. 2005. Vinylogous amide analogs of methylphenidate. Bioorg. Med. Chem. Lett. 15: 3044–3047.
   PubMed Web of Science ®Google Scholar
• Gardner, C. R., Almarsson, O., Chen, H., Morissette, S., Peterson, M., Zhang, Z., Wang, S., and Cima, M. 2004. Application of high throughput technologies to drug substance and drug product development. Comput. Chem. Eng. 28: 943–953.
   Web of Science ®Google Scholar
• Ghosh, S., Hoselto, S. A., Dorsam, G. P., and Schuh, J. M. 2013. Eosinophils in fungus-associated allergic pulmonary disease. Front. Pharmacol. 4: 8.
   Google Scholar
• Gould, P. L. 1986. Salt selection for basic drugs. Int. J. Pharm. 33: 201–217.
   Web of Science ®Google Scholar
• Kaminuma, O., Ogawa, K., Kikkawa, H., Kikuchi, M., Naito, K., and Ikezawa, K. 1998. A novel anti-allergic drug, betotastine besilate, suppresses interleukin-5 production by human peripheral blood mononuclear cells. Biol. Pharm. Bull. 21: 411–413.
   PubMed Web of Science ®Google Scholar
• Kato, M., Nishida, A., Aga, Y., Kita, J., Kudo, Y., Narita, H., and Endo, T. 1997. Pharmaco-kinetic and pharmacodynamic evaluation of central effect of the novel anti- allergic agent betotastine besilate. Arzneimittelforschung 47: 1116–1124.
   PubMed Web of Science ®Google Scholar
• Kida, T., Fujii, A., Sakai, O., Iemura, M., Atsumi, I., Wada, T., and Sakaki, H. 2010. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models. Exp. Eye Res. 91: 85–91.
   PubMed Web of Science ®Google Scholar
• Kim, B. H., Chung, J. Y., Kim, J. R., Lim, K. S., Lim, H. S., Yu, K. S., Jang, I. J., and Shin,S. G. 2007. Pharmacokinetic characteristics of bepotastinebesilate in healthy subjects. Kor. J. Clin. Pharmacol. Ther. 15: 37–45.
   Google Scholar
• Lee, T., and Wang, Y. W. 2009. Initial salt screening procedures for manufacturing ibuprofen. Drug Dev. Ind. Pharm. 35: 555–567.
   PubMed Web of Science ®Google Scholar
• Leurs, R., Church, M. K., and Taglialatela, M. 2002. H1-antihistamines: Inverse agonism, anti-inflammatory actions and cardiac effects. Clin. Exp. Allergy 32: 489–498.
   PubMed Web of Science ®Google Scholar
• Li, D. X., Oh, Y. K., Lim, S. J., Kim, J. O., Yang, H. J., Sung, J. H., Young, C. H., and Choi, H. G. 2008. Novel gelatin microcapsule with bioavailability enhancement of ibuprofen using spray-drying technique. Int. J. Pharm. 355: 277–284.
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A. 2000. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44: 235–249.
   PubMed Web of Science ®Google Scholar
• Lippert, U., Möller, A., Welker, P., Artuc, M., and Henz, B. M. 2000. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp. Dermatol. 9: 118–124.
   PubMed Web of Science ®Google Scholar
• Loeser, E., Sutton, P., Skorodinsky, A., Lin, M., and Yowell, G. 2012. Chemical interactions between an active pharmaceutical ingredient and its counter ion in a tromethamine salt under forced degradation conditions. Drug Dev. Ind. Pharm. 38: 357–364.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson, K. A. 2010. Oral bepotastine: In allergic disorders. Drugs 70: 1579–1591.
   PubMed Web of Science ®Google Scholar
• McCabe, C. F., and McCabe, S. E. 2012. Comparative efficacy of bepotastinebesilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference. Clin. Ophthalmol. 6: 1731–1738.
   PubMedGoogle Scholar
• Melvin, T. A., and Ramanathan, M., Jr. 2012. Role of innate immunity in the pathogenesis of allergic rhinitis. Curr. Opin. Otolaryngol. Head Neck Surg. 20: 194–198.
   PubMed Web of Science ®Google Scholar
• Narita, H., Kikuchi, M., Asahi, T., Inamatsu, M., Odawara, A., Kinoshita, K., Shimazaki, T., Hoshiyama, M., Magaribuchi, T., Yamamura, M., Yato, N., and Yoneda, H. 1997. General pharmacology of betotastine besilate (TAU-284). Jpn. Pharmacol. Ther. 25: 907–924.
   Google Scholar
• Nelson, E. 1957. Solution rate of theophylline salts and effects from oral administration. J. Am. Pharm. Assoc. 46: 607–614.
   Google Scholar
• Nelson, E. 1958. Comparative dissolution rates of weak acids and their sodium salts. J. Am. Pharm. Assoc. 47: 297–299.
   Google Scholar
• Otsuka, M., and Tanabe, H. 2012. Stability test for amorphous materials in humidity controlled 96-well plates by near-infrared spectroscopy. Drug Dev. Ind. Pharm. 38: 380–385.
   PubMed Web of Science ®Google Scholar
• Sakai, A., Kikuchi, M., Yato, N., Kikkawa, S., Saito, N., and Narita, H. 1997. Inhibitory effect of betotastine besilate on antigen-induced airway eosinophil infiltration and peripheral blood eosinophilia in mice. Arzneimittelforschung 47: 954–958.
   PubMed Web of Science ®Google Scholar
• Scadding, G. 2005. Predicting and establishing the clinical efficacy of a histamine H(1)-receptor antagonist: Desloratadine,the model paradigm. Clin. Drug Investig. 25:153–164.
   PubMed Web of Science ®Google Scholar
• Schneider, E., Leite-de-Moraes, M., and Dy, M. 2010. Histamine, immune cells and autoimmunity. Adv. Exp. Med. Biol. 709: 81–94.
   PubMed Web of Science ®Google Scholar
• Serajuddin, A. T. 2007. Salt formation to improve drug solubility. Adv. Drug Deliv. Rev. 59: 603–616.
   PubMed Web of Science ®Google Scholar
• Shore, P. A., Brodie, B. B., and Hogben, C. A. M. 1957. The gastric secretion of drugs: A pH partition hypothesis. J. Pharmacol. Exp. Ther. 119: 361–369.
   PubMed Web of Science ®Google Scholar
• Simons, F. E., and Simons, K. J. 2011. Histamine and H1-antihistamines: Celebrating a century of progress. J. Allergy Clin. Immunol. 128: 1139–1150.
   PubMed Web of Science ®Google Scholar
• Stahl, S. M. 2008. Selective histamine H1 antagonism: Novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectrums 13: 1027–1038.
   PubMed Web of Science ®Google Scholar
• Stahl, P. H., and Wermuth, C. G. 2002. Handbook of pharmaceutical salts: Properties, selection and use. Weinheim, Germany: Wiley-VCH.
   Google Scholar
• Stahl, H. P., and Wermuth, C. G. 2011. Handbook of pharmaceutical salts: Properties, selection, and use, 2nd rev. ed. Hoboken, NJ: Wiley.
   Google Scholar
• Sweet, D. V. 1997. Registry of Toxic Effects of Chemical Substances, Rtecs: A comprehensive guide. Diane Publishing Co. NIOSH, Cincinnati, Ohio.
   Google Scholar
• Takemoto, M., Yamamoto, Y., and Achiwa, K. 1996. Effect of inhibitor or immobilization on reduction of benzoylpyridines by Baker’s yeast. Chem. Pharm. Bull. (Tokyo) 44: 853–855.
   PubMedGoogle Scholar
• Ueno, M., Inagaki, N., Nagai, H., and Koda, A. 1998. Antiallergic action of betotastine besilate (TAU-284) in animal models: A comparison with ketotifen. Pharmacology 57: 206–214.
   PubMed Web of Science ®Google Scholar
• Valent, P., Gleich, G. J., Reiter, A., Roufosse, F., Weller, P. F., Hellmann, A., Metzgeroth, G., Leiferman, K. M., Arock, M., Sotlar, K., Butterfield, J. H., Cerny-Reiterer, S., Mayerhofer, M., Vandenberghe, P., Haferlach, T., Bochner, B. S., Gotlib, J., Horny, H. P., Simon, H. U., and Klion, A. D. 2012. Pathogenesis and classification of eosinophil disorders: A review of recent developments in the field. Expert Rev. Hematol. 5: 157–176.
   PubMed Web of Science ®Google Scholar
• Van de Waterbeemd H, Smith DA, Beaumont K, and Walker DK. 2001. Property-based design: Optimization of drug absorption and pharmacokinetics. J. Med. Chem. 44: 1313–1333.
   PubMed Web of Science ®Google Scholar
• Williams, J. I., Gow, J. A., Klier, S. M., McCue, S. L., Salapatek, A. M., and McNamara, T. R. 2010. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Curr. Med. Res. Opin. 26: 2329–2338.
   PubMed Web of Science ®Google Scholar
• Williams, J. I., Kennedy, K. S., Gow, J. A., Torkildsen, G. L., Abelson, M. B., Gomes, P. J., and McNamara, T. R. 2011. Bepotastine Besilate Ophthalmic Solutions Study Group. 2011. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis. J. Ocul. Pharmacol. Ther. 27:385–393.
   PubMed Web of Science ®Google Scholar
• Wroblewski, T., Graul, A., and Castañer, J. 1988. Brinzolamide antiglaucoma, carbonic anhydrase inhibitor. Drugs Future 23: 365–369.
   Google Scholar